Dario Altieri
Dario Carlo Altieri | |
|---|---|
| Occupation | Researcher |
Dario Carlo Altieri, an Italian-born physician-scientist, is the president and CEO of The Wistar Institute[1] in Philadelphia.[2] He is also the holder of the Robert and Penny Fox Distinguished Professor and the director of the National Cancer Institute-designated Ellen and Ronald Caplan Cancer Center at The Wistar Institute.
Biography[edit]
Altieri was born in Milan, Italy, where he attended the University of Milan Medical School. He trained in internal medicine with a postgraduate specialty degree in clinical and experimental hematology. In 1987, he joined the Scripps Clinic and Research Foundation in La Jolla, California, as a research fellow before becoming a faculty member[3]. In 1994, Altieri became an associate professor in the Department of Pathology, Boyer Center for Molecular Medicine at Yale University School of Medicine, and was promoted to full professor in 1999[3]. In 2002, he became the founding Chair of the Department of Cancer Biology at the University of Massachusetts Medical School.[1][4]
Research[edit]
His research has focused on Inhibitors of Apoptosis (IAP), a family of genes essential for proliferation and survival of cells. His work has identified survivin, one of these IAP genes, is over-produced in almost every human cancer, and his team is currently studying the biology of survivin and how it could be used to develop treatments for cancer.[5][6][7]
Altieri has also been involved in the development of gamitrinib, a Hsp90 inhibitor that was shown to disable the activity of mitochondria in cancerous cells.
In 2013, Altieri and his team received a $1.5 million grant from the United States Department of Defense to prepare the drug for human trials.[8][9] He also co-founded the Cancer Biology Training Consortium and the Pancreatic Cancer alliance in 2005.[10]
Further reading[edit]
- "Dario C. Altieri Inventions, Patents and Patent Applications". Justia Patents Search. 2021-12-23. Retrieved 2023-03-15.<
- "A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer - Full Text View". ClinicalTrials.gov. 2021-04-01. Retrieved 2023-03-15.
References[edit]
- ^ a b "Dario C. Altieri: Chief Executive Officer of Wistar Institute". The University of Pennsylvania. Retrieved 2 March 2015.
- ^ "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute. Retrieved 11 February 2014.
- ^ a b "Biography Dario C. Altieri, MD.; Association of American Cancer Institutes".
- ^ "Gene "survivin" inhibits cell death" (PDF). Yale Cancer Center. Retrieved 2023-03-15.
- ^ "Dario C. Altieri, M.D." The Wistar Institute. Retrieved 28 January 2014.
- ^ "Thrivin' (not just survivin') in Philadelphia". The Journal of Clinical Investigation. Retrieved 28 January 2014.
- ^ "Emerging Research Fronts - 2009". ScienceWatch. Retrieved 11 February 2014.
- ^ "Wistar Receives $1.5 Million Department of Defense Grant To Ready Potential Prostate Drug For Clinical Use". The Wistar Institute. Archived from the original on 22 February 2014. Retrieved 28 January 2014.
- ^ "Combinatorial Drugs Target Cancer Cell Mitochonndria". biotechdaily.com. Retrieved 11 February 2014.
- ^ "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute. Retrieved 28 January 2014.
External links[edit]
- Dr. Altieri's homepage on The Wistar Institute's website Archived 2014-02-22 at the Wayback Machine